Towards a solution for the access challenges faced by combination treatments

In this article, Takeda UK present their Value Attribution and Voluntary Arbitration Frameworks, a potential solution for the combination treatment challenge.

COMBINATION treatments can result in improved outcomes for patients; however, they may present a cost effectiveness challenge, especially when multiple on-patent treatments are combined. Combination treatments often include a novel ‘add-on’ therapy coupled with a ‘backbone’ treatment and can face difficulty navigating the health technology assessment (HTA) process and attaining reimbursement especially in cost-effective markets. This article looks at the problems identified and explores a potential solution for the pharmaceutical industry and broader healthcare community to consider and work together to deliver.